Ikarian Capital’s Pfizer PFE Stock Holding History

Ikarian Capital’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-80,000	Closed	-$4.19M	–	150
2022 Q2	$4.19M	Hold	80,000	–	–	0.76%	43
2022 Q1	$4.14M	Buy	+80,000	New	+$4.15M	0.54%	46

Other funds holding PFE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Ikarian Capital's PFE Position: Q3 2022 in Review

Ikarian Capital sold out of Pfizer (PFE) in Q3 2022, closing a stake of 80,000 shares — an estimated $4.19M sold.

Ikarian Capital first reported a position in PFE in Q1 2022 and held it in 2 quarters. The position peaked at $4.19M in Q2 2022. 3,086 funds tracked by Wall St. Rank hold PFE as of Q3 2022.

Ikarian Capital reported no remaining Pfizer position as of Q3 2022 after selling out during the quarter.
Ikarian Capital sold 80,000 Pfizer shares in Q3 2022, an estimated $4.19M.
Ikarian Capital first reported a position in Pfizer in Q1 2022 and held it in 2 quarters.
Ikarian Capital's Pfizer position peaked at $4.19M in Q2 2022.
3,086 funds tracked by Wall St. Rank held Pfizer as of Q3 2022.

Based on Ikarian Capital's 13F filing for Q3 2022, filed 14 Nov 2022.